Opioid Withdrawal Medications and Treatment Options

Key Takeaways

• ASAM (American Society of Addiction Medicine) guidelines recommend medication-assisted withdrawal management over unmedicated detox for opioid use disorder.
• Buprenorphine (Suboxone/Sublocade) is the most effective single medication for opioid withdrawal, reducing symptoms while also serving as a bridge to long-term medication-assisted treatment (MAT).
• Clonidine addresses sympathetic nervous system symptoms — elevated heart rate, sweating, anxiety — but does not reduce cravings.
• Methadone (Dolophine/Methadose) taper protocols are used in inpatient settings and opioid treatment programs (OTPs) for individuals who cannot be inducted onto buprenorphine.
• Detox alone — without transition to ongoing MAT or behavioral treatment — has consistently poor outcomes and high relapse rates.
• New Jersey provides multiple pathways to medically supervised withdrawal management through DMHAS-licensed facilities.

Opioid withdrawal is a medically manageable condition. The medications and protocols available today can substantially reduce suffering, lower complication risk, and serve as the entry point for sustained recovery. However, how withdrawal is managed matters enormously. The clinical approach — which medications are used, how they are dosed, and whether detox is connected to ongoing treatment — directly influences both immediate comfort and long-term outcomes.

This guide covers the current evidence-based approaches to opioid withdrawal management, the specific medications used, and how to access treatment in New Jersey.

Clinical Approaches to Opioid Withdrawal Management

ASAM Guidelines Overview

The American Society of Addiction Medicine (ASAM) publishes clinical guidelines that represent the standard of care for opioid withdrawal management. Key principles from ASAM’s National Practice Guideline include:

• Medication-assisted withdrawal is preferred over unmedicated “cold turkey” approaches. ASAM explicitly recommends against unsupervised, unmedicated withdrawal due to high relapse rates and medical risks.
• Withdrawal management should be viewed as a bridge to ongoing treatment, not a standalone intervention. ASAM’s guidelines emphasize that detox without subsequent care is clinically incomplete.
• The choice of medication should be individualized based on the opioid used, severity of dependence, co-occurring conditions, patient preference, and available treatment settings.
• Patients should be offered ongoing MAT at the conclusion of the withdrawal management episode. Buprenorphine (Suboxone/Sublocade), methadone (Dolophine/Methadose), and naltrexone (Vivitrol) are all recommended options for ongoing opioid use disorder treatment.

The ASAM criteria also define levels of care for withdrawal management, ranging from Level 1-WM (ambulatory withdrawal management without extended on-site monitoring) through Level 4-WM (medically managed intensive inpatient withdrawal management). The appropriate level depends on medical severity, co-occurring conditions, and available support systems.

Inpatient vs. Outpatient Detox

Inpatient (residential) detox provides 24-hour medical monitoring and is recommended for:

• Individuals with severe physical dependence, particularly on high-dose fentanyl
• Those with co-occurring alcohol or benzodiazepine dependence (which carry seizure risk)
• Patients with significant medical conditions that complicate withdrawal
• Individuals without stable housing or social support during the detox period
• Those who have previously failed outpatient detox attempts

Outpatient (ambulatory) detox allows individuals to withdraw at home while receiving medication and regular clinical check-ins. This approach works best for:

• Individuals with mild to moderate physical dependence
• Patients with stable housing and support systems
• Those able to attend frequent medical appointments
• Individuals being inducted onto buprenorphine (Suboxone/Sublocade) for ongoing MAT

In New Jersey, both inpatient and outpatient detox settings are regulated by the Division of Mental Health and Addiction Services (DMHAS). The NJ Substance Abuse Treatment Hotline (1-844-276-2777) can connect individuals with appropriate programs based on their clinical needs.

Medications Used in Opioid Withdrawal

Clonidine for Symptom Relief

Clonidine is an alpha-2 adrenergic agonist that was one of the first medications used specifically for opioid withdrawal management. It works by dampening the overactive sympathetic nervous system response that drives many withdrawal symptoms.

What clonidine addresses effectively:

• Elevated heart rate and blood pressure
• Sweating and chills
• Anxiety and agitation
• Muscle aches (partially)
• Rhinorrhea and lacrimation

What clonidine does not address:

• Drug cravings
• Insomnia (may actually worsen sedation-related issues)
• GI symptoms (nausea, vomiting, diarrhea)
• Bone and muscle pain (only partially effective)

Clonidine is typically dosed at 0.1 to 0.3 mg every 6 to 8 hours, with careful blood pressure monitoring to avoid hypotension. It is most useful as an adjunctive medication — paired with buprenorphine or other symptom-targeted drugs — rather than as a standalone withdrawal treatment. When used alone, clonidine-based protocols show higher dropout rates than buprenorphine-based approaches.

Buprenorphine (Subutex/Suboxone)

Buprenorphine is a partial mu-opioid agonist that represents the most significant advancement in opioid withdrawal management. It is available in several formulations:

• Suboxone (buprenorphine/naloxone sublingual film or tablet) — the most commonly prescribed formulation. The naloxone (Narcan) component discourages misuse by injection.
• Subutex (buprenorphine alone) — used primarily during pregnancy when naloxone is avoided
• Sublocade (extended-release buprenorphine injection) — a monthly injection that ensures medication adherence

As a partial agonist, buprenorphine activates opioid receptors enough to relieve withdrawal symptoms and reduce cravings, but has a “ceiling effect” that limits respiratory depression risk. This pharmacological profile makes it both effective and significantly safer than full agonists.

Buprenorphine induction requires careful timing. Treatment generally begins when a patient is already in moderate withdrawal (COWS score of 12 or higher) to avoid precipitated withdrawal — a rapid, intense worsening of symptoms caused by buprenorphine displacing full agonists from opioid receptors.

For patients transitioning from fentanyl, induction protocols have evolved. Some clinicians now use micro-dosing (Bernese method) approaches that introduce very small buprenorphine doses while the patient is still using opioids, gradually increasing until the transition is complete. This approach can reduce the risk of precipitated withdrawal from fentanyl, which can be particularly severe.

Methadone Taper Protocols

Methadone (Dolophine/Methadose) is a full mu-opioid agonist with a long half-life. In the context of withdrawal management, it can be used in two ways:

1. Short-term taper: Starting at a dose sufficient to control symptoms (typically 20 to 30 mg/day) and gradually reducing over 7 to 14 days in an inpatient setting.
2. Transition to maintenance: Initiating methadone during the withdrawal period and continuing as ongoing MAT. This approach has the strongest evidence base for individuals with severe opioid use disorder.

Methadone for opioid use disorder can only be dispensed through federally certified Opioid Treatment Programs (OTPs). New Jersey has multiple OTPs across the state. Unlike buprenorphine, methadone cannot be prescribed by individual physicians in office-based settings for the treatment of opioid use disorder.

Adjunctive Medications and Comfort Care

Anti-Nausea and Anti-Diarrheal Drugs

GI symptoms are among the most distressing aspects of withdrawal, and several medications help manage them:

• Ondansetron (Zofran): A serotonin receptor antagonist commonly used for nausea and vomiting. Effective and generally well-tolerated.
• Promethazine (Phenergan): An antihistamine with strong anti-nausea properties. Also provides mild sedation.
• Loperamide (Imodium): An over-the-counter opioid receptor agonist that acts only in the gut (does not cross the blood-brain barrier). Effective for diarrhea management.
• Bismuth subsalicylate (Pepto-Bismol): Provides modest relief for nausea and diarrhea.
• IV fluid replacement: In inpatient settings, IV hydration with electrolyte monitoring is standard for patients with severe GI symptoms.

Sleep Aids and Muscle Relaxants

Sleep disruption and musculoskeletal pain are typically addressed with:

• Trazodone: A sedating antidepressant commonly used for insomnia during withdrawal. Non-addictive and generally safe.
• Hydroxyzine (Vistaril): An antihistamine that addresses both anxiety and insomnia without abuse potential.
• Tizanidine or cyclobenzaprine: Muscle relaxants that provide relief from the severe muscle aches and restless legs common during withdrawal.
• Dicyclomine (Bentyl): An antispasmodic that can help with abdominal cramping.
• NSAIDs (ibuprofen, naproxen): Over-the-counter anti-inflammatory medications provide modest pain relief without opioid receptor activity.

Benzodiazepines are generally avoided during opioid withdrawal due to their own addiction potential, though they may be used short-term in clinical settings when anxiety or insomnia is severe and other options have been insufficient.

Emergency Medicine and Acute Withdrawal Crises

When Withdrawal Becomes a Medical Emergency

While opioid withdrawal itself is rarely fatal, certain circumstances elevate the risk:

• Severe dehydration from uncontrolled vomiting and diarrhea — the most common medical emergency during opioid withdrawal
• Concurrent benzodiazepine or alcohol withdrawal — these substances carry seizure risk and can be life-threatening
• Withdrawal during pregnancy — can cause fetal distress, preterm labor, and miscarriage
• Pre-existing cardiac conditions — the sympathetic surge during withdrawal stresses the cardiovascular system
• Withdrawal in jail or correctional settings — inadequate medical supervision in these environments has been linked to deaths from dehydration and other complications

ER Protocols for Opiate Withdrawal

When an individual presents to a New Jersey emergency department in opioid withdrawal, standard protocols include:

• Vital sign assessment and COWS scoring
• IV fluid resuscitation if dehydrated
• Anti-emetic and anti-diarrheal medications
• Clonidine or buprenorphine for symptom management (New Jersey emergency departments are increasingly authorized to initiate buprenorphine)
• Assessment for co-occurring substance use and medical conditions
• Referral to follow-up treatment — NJ CARES facilitates warm handoffs from emergency departments to treatment providers

Under New Jersey’s emergency department initiatives, many hospitals now have addiction medicine consultants or peer recovery specialists available to connect patients with treatment during the critical window after an ER visit.

Transitioning from Detox to Ongoing Treatment

The Case for Continued MAT

The most critical decision point in the withdrawal management process is what happens after acute symptoms resolve. Research consistently demonstrates that detox without ongoing treatment produces outcomes barely better than no treatment at all. NIDA has reported that individuals who complete detox but do not receive follow-up care return to opioid use at rates exceeding 80% within one year.

This is why ASAM, NIDA, and SAMHSA all recommend that withdrawal management be explicitly connected to a plan for ongoing care — ideally including medication-assisted treatment with buprenorphine (Suboxone/Sublocade), methadone (Dolophine/Methadose), or naltrexone (Vivitrol).

Each of these medications serves a different role in ongoing treatment:

• Buprenorphine reduces cravings and blocks the effects of other opioids. Can be prescribed in office-based settings.
• Methadone provides full opioid receptor activation at controlled doses, eliminating withdrawal and reducing cravings. Requires daily dispensing at an OTP initially.
• Naltrexone (Vivitrol) is an opioid antagonist that blocks opioid effects entirely. Requires complete detox before initiation and is available as a monthly injection.

Connecting to Treatment After Detox in NJ

New Jersey has implemented several systems to improve the transition from detox to ongoing care:

• NJ CARES: Coordinates rapid access to treatment, including same-day or next-day appointments
• Recovery support specialists: Many NJ detox programs employ peer recovery specialists who help individuals navigate the transition to outpatient treatment
• NJ Medicaid expansion: Covers MAT, behavioral therapy, and recovery support services for eligible residents
• The 2019 NJ MAT Access Act: Expanded requirements for insurance coverage of medication-assisted treatment

For individuals completing detox, the pillar guide to opioid addiction provides a comprehensive overview of treatment pathways. Specific information about buprenorphine (Suboxone) treatment is also available for those considering this option.

---

This article is part of our complete guide to opioid addiction in New Jersey. For a timeline of what to expect during withdrawal, see opioid withdrawal symptoms timeline. For information about Suboxone specifically, see Suboxone treatment: how it works.

For more on ASAM criteria and levels of care, visit our ASAM criteria glossary entry. For information about MAT options, see our guide to medication-assisted treatment.